Global Hydroxyprogesterone Caproate Injection Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Hydroxyprogesterone Caproate Injection Market Research Report 2024
Hydroxyprogesterone caproate (OHPC), sold under the brand names Proluton and Makena among others, is a progestin medication which is used to prevent preterm birth in pregnant women with a history of the condition and to treat gynecological disorders.It has also been formulated in combination with estrogens for various indications (brand names Gravibinon and Primosiston) and as a form of long-lasting injectable birth control (brand name Chinese Injectable No. 1). It is not used by mouth and is instead given by injection into muscle or fat, typically once per week to once per month depending on the indication.
According to Mr Accuracy reports’s new survey, global Hydroxyprogesterone Caproate Injection market is projected to reach US$ 292.3 million in 2034, increasing from US$ 263 million in 2022, with the CAGR of 1.5% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Hydroxyprogesterone Caproate Injection market research.
Global hydroxyprogesterone caproate injection main manufactuers include AMAG Pharmaceuticals, Mcguff Pharmaceuticals and Aspen, etc., totally holding a share for 97% of the market. North America is the largest market of hydroxyprogesterone caproate injection, with a share about 37%. As for the types of products, it can be divided into 1 ml injection(including 1.1 mL) and 5 ml injection. The most common product is 5 ml injection, with a share over 52%. In terms of applications, it is widely used in hospitals and clinics. The most commom application is in hospitals, with a share over 50%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Hydroxyprogesterone Caproate Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
AMAG Pharmaceuticals
Mcguff Pharmaceuticals Inc
Aspen Oss B.V
American Regent, Inc.
Mylan Institutional
Segment by Type
1 mL Injection(Including 1.1 mL)
5 mL Injection
Hospitals Injection
Clinics Injection
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Hydroxyprogesterone Caproate Injection report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Hydroxyprogesterone Caproate Injection market is projected to reach US$ 292.3 million in 2034, increasing from US$ 263 million in 2022, with the CAGR of 1.5% during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Hydroxyprogesterone Caproate Injection market research.
Global hydroxyprogesterone caproate injection main manufactuers include AMAG Pharmaceuticals, Mcguff Pharmaceuticals and Aspen, etc., totally holding a share for 97% of the market. North America is the largest market of hydroxyprogesterone caproate injection, with a share about 37%. As for the types of products, it can be divided into 1 ml injection(including 1.1 mL) and 5 ml injection. The most common product is 5 ml injection, with a share over 52%. In terms of applications, it is widely used in hospitals and clinics. The most commom application is in hospitals, with a share over 50%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Hydroxyprogesterone Caproate Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
AMAG Pharmaceuticals
Mcguff Pharmaceuticals Inc
Aspen Oss B.V
American Regent, Inc.
Mylan Institutional
Segment by Type
1 mL Injection(Including 1.1 mL)
5 mL Injection
Segment by Application
Hospitals Injection
Clinics Injection
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Hydroxyprogesterone Caproate Injection report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices